SE168308C1 - - Google Patents

Info

Publication number
SE168308C1
SE168308C1 SE168308DA SE168308C1 SE 168308 C1 SE168308 C1 SE 168308C1 SE 168308D A SE168308D A SE 168308DA SE 168308 C1 SE168308 C1 SE 168308C1
Authority
SE
Sweden
Application number
Publication of SE168308C1 publication Critical patent/SE168308C1/xx

Links

SE168308D SE168308C1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE168308T

Publications (1)

Publication Number Publication Date
SE168308C1 true SE168308C1 (de)

Family

ID=41958801

Family Applications (1)

Application Number Title Priority Date Filing Date
SE168308D SE168308C1 (de)

Country Status (1)

Country Link
SE (1) SE168308C1 (de)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004017964A1 (en) 2002-08-19 2004-03-04 Pfizer Products Inc. Combination therapy for hyperproliferative diseases
WO2007062314A2 (en) 2005-11-23 2007-05-31 Bristol-Myers Squibb Company Heterocyclic cetp inhibitors
WO2008070496A2 (en) 2006-12-01 2008-06-12 Bristol-Myers Squibb Company N- ( (3-benzyl) -2, 2- (bis-phenyl) -propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases
EP2392567A1 (de) 2005-10-21 2011-12-07 Bristol-Myers Squibb Company Benzothiazinderivate und ihre verwendung als lxr-modulatoren
WO2014029841A1 (en) 2012-08-23 2014-02-27 Cardiolynx Ag Extended release compositions of an aminoalkyl nitrate
WO2014170786A1 (en) 2013-04-17 2014-10-23 Pfizer Inc. N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
WO2016135263A1 (en) 2015-02-27 2016-09-01 Armin Scherhag No donors for the treatment of stress-induced pulmonary haemorrhage in animals
WO2020150473A2 (en) 2019-01-18 2020-07-23 Dogma Therapeutics, Inc. Pcsk9 inhibitors and methods of use thereof

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004017964A1 (en) 2002-08-19 2004-03-04 Pfizer Products Inc. Combination therapy for hyperproliferative diseases
EP2392567A1 (de) 2005-10-21 2011-12-07 Bristol-Myers Squibb Company Benzothiazinderivate und ihre verwendung als lxr-modulatoren
WO2007062314A2 (en) 2005-11-23 2007-05-31 Bristol-Myers Squibb Company Heterocyclic cetp inhibitors
WO2008070496A2 (en) 2006-12-01 2008-06-12 Bristol-Myers Squibb Company N- ( (3-benzyl) -2, 2- (bis-phenyl) -propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases
WO2014029841A1 (en) 2012-08-23 2014-02-27 Cardiolynx Ag Extended release compositions of an aminoalkyl nitrate
WO2014170786A1 (en) 2013-04-17 2014-10-23 Pfizer Inc. N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
WO2016135263A1 (en) 2015-02-27 2016-09-01 Armin Scherhag No donors for the treatment of stress-induced pulmonary haemorrhage in animals
WO2020150473A2 (en) 2019-01-18 2020-07-23 Dogma Therapeutics, Inc. Pcsk9 inhibitors and methods of use thereof

Similar Documents

Publication Publication Date Title
CN1681495B (zh) 用于治疗过度增生性疾病的组合物
EP2392567B1 (de) Benzothiazinderivate und ihre verwendung als lxr-modulatoren
AU2020209215B2 (en) PCSK9 inhibitors and methods of use thereof
AU2006318310B2 (en) Heterocyclic CETP inhibitors
CA2909442A1 (en) N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
CA2907071A1 (en) Substituted amide compounds
AU2013304942A1 (en) Extended release compositions of an aminoalkyl nitrate
EP2094643B1 (de) N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-aminderivate als cetp-hemmer für die behandlung von atherosklerose und herz-kreislauf-erkrankungen
SE168308C1 (de)